Completed PHASE2 INTERVENTIONAL 4-arm NCT00307749

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy

Sponsor: Tanabe Pharma Corporation

Conditions Diabetic Polyneuropathy

Interventions MCC-257 Placebo

Updated 6 times since 2017 Last updated: Dec 26, 2007 Started: Mar 31, 2006 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetic Polyneuropathy and is currently completed. Tanabe Pharma Corporation leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Jan 2026 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.